Paradice Investment Management LLC Has $26.67 Million Stock Holdings in Tandem Diabetes Care, Inc. $TNDM

Paradice Investment Management LLC lifted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 24.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,196,468 shares of the medical device company’s stock after purchasing an additional 429,289 shares during the quarter. Tandem Diabetes Care comprises 6.0% of Paradice Investment Management LLC’s holdings, making the stock its 9th biggest position. Paradice Investment Management LLC owned approximately 3.25% of Tandem Diabetes Care worth $26,665,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Tandem Diabetes Care by 8.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company’s stock worth $319,000 after acquiring an additional 1,384 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in Tandem Diabetes Care by 10.1% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company’s stock worth $285,000 after purchasing an additional 1,399 shares in the last quarter. State of Wyoming increased its holdings in Tandem Diabetes Care by 49.1% during the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company’s stock worth $86,000 after purchasing an additional 1,471 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Tandem Diabetes Care by 8.0% in the 1st quarter. Advisors Asset Management Inc. now owns 22,460 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 1,664 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 8.9% in the second quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company’s stock valued at $391,000 after purchasing an additional 1,719 shares in the last quarter.

Analyst Ratings Changes

TNDM has been the topic of a number of recent research reports. Baird R W raised Tandem Diabetes Care from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Wall Street Zen raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley set a $23.00 target price on shares of Tandem Diabetes Care and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Robert W. Baird set a $30.00 price target on shares of Tandem Diabetes Care and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Finally, Citigroup increased their price objective on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.94.

Tandem Diabetes Care Stock Down 0.1%

TNDM opened at $22.33 on Tuesday. The stock’s fifty day simple moving average is $19.02 and its 200 day simple moving average is $16.11. Tandem Diabetes Care, Inc. has a 1-year low of $9.98 and a 1-year high of $38.28. The stock has a market cap of $1.51 billion, a PE ratio of -7.32 and a beta of 1.68. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The firm had revenue of $249.25 million for the quarter, compared to analysts’ expectations of $235.80 million. Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The business’s revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.35) EPS. As a group, research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.